|
1) Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Sci. 2009; 100: 1366-73
|
|
|
|
2) Raleigh JA, Chou SC, Arteel GE, et al. Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors. Radiat Res. 1999; 151: 580-9
|
|
|
|
|
|
3) Markus R, Reutens DC, Kazui S, et al. Topography and temporal evolution of hypoxic viable tissue identified by 18F-fluoromisonidazole positron emission tomography in humans after ischemic stroke. Stroke. 2003; 34: 2646-52
|
|
|
|
|
|
4) Markus R, Reutens DC, Kazui S, et al. Hypoxic tissue in ischaemic stroke: persistence and clinical consequences of spontaneous survival. Brain. 2004; 127: 1427-36
|
|
|
|
|
|
5) Martin GV, Caldwell JH, Graham MM, et al. Noninvasive detection of hypoxic myocardium using fluorine-18-fluoromisonidazole and positron emission tomography. J Nucl Med. 1992; 33: 2202-8
|
|
|
|
|
|
6) Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 3: 721-32
|
|
|
|
|
|
7) McKay LC, Critchley HD, Murphy K, et al. Subcortical and brainstem sites associated with chemostimulated increases in ventilation in humans. Neuroimage. 2010; 49: 2526-35
|
|
|
|
|
|
8) Chan KC, Xing KK, Cheung MM, et al. Functional MRI of postnatal visual development in normal and hypoxic-ischemic-injured superior colliculi. Neuroimage. 2010; 49: 2013-20
|
|
|
|
|
|
9) Vincent K, Moore J, Kennedy S, et al. Blood oxygenation level dependent functional magnetic resonance imaging: current and potential uses in obstetrics and gynaecology. BJOG. 2009; 116: 240-6
|
|
|
|
|
|
10) Krohn KA, Link JM, Mason RP. Molecular imaging of hypoxia. J Nucl Med. 2008; 49 Suppl 2: 129S-48S
|
|
|
|
|
|
11) Troost EG, Laverman P, Philippens ME, et al. Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging. 2008; 35: 1803-11
|
|
|
|
|
|
12) Nehmeh SA, Lee NY, Schroder H, et al. Reproducibility of intratumor distribution of 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008; 70: 235-42
|
|
|
|
|
|
13) Read SJ, Hirano T, Abbott DF, et al. Identifying hypoxic tissue after acute ischemic stroke using PET and 18F-fluoromisonidazole. Neurology. 1998; 51: 1617-21
|
|
|
|
|
|
14) Sarrafzadeh AS, Nagel A, Czabanka M, et al. Imaging of hypoxic-ischemic penumbra with 18F-fluoromisonidazole PET/CT and measurement of related cerebral metabolism in aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2010; 30: 36-45
|
|
|
|
|
|
15) Dence CS, Ponde DE, Welch MJ, et al. Auto-radiographic and small-animal PET comparisons between 18F-FMISO, 18F-FDG, 18F-FLT and the hypoxic selective 64Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 2008; 35: 713-20
|
|
|
|
|
|
16) Wang W, Georgi JC, Nehmeh SA, et al. Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging. Phys Med Biol. 2009; 54: 3083-99
|
|
|
|
|
|
17) Wang W, Lee NY, Georgi JC, et al. Pharmacokinetic analysis of hypoxia 18F-fluoro-misonidazole dynamic PET in head and neck cancer. J Nucl Med. 2010; 51: 37-45
|
|
|
|
|
|
18) Wang K, Yorke E, Nehmeh SA, et al. Modeling acute and chronic hypoxia using serial images of 18F-FMISO PET. Med Phys. 2009; 36: 4400-8
|
|
|
|
|
|
19) Szeto MD, Chakraborty G, Hadley J, et al. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas. Cancer Res. 2009; 69: 4502-9
|
|
|
|
|
|
20) Swanson KR, Chakraborty G, Wang CH, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009; 50: 36-44
|
|
|
|
|
|
21) Busk M, Horsman MR, Jakobsen S, et al. Imaging hypoxia in xenografted and murine tumors with 18F-fluoroazomycin arabinoside: a comparative study involving microPET, autoradiography, PO2-polarography, and fluorescence microscopy. Int J Radiat Oncol Biol Phys. 2008; 70: 1202-12
|
|
|
|
|
|
22) Busk M, Horsman MR, Jakobsen S, et al. Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging. 2008; 35: 2294-303
|
|
|
|
|
|
23) Kumar P, Naimi E, McEwan AJ, et al. Synthesis, radiofluorination, and hypoxia-selective studies of FRAZ: A configurational and positional analogue of the clinical hypoxia marker, [18F]-FAZA. Bioorg Med Chem. 2010; 18: 2255-64
|
|
|
|
|
|
24) Riedl CC, Brader P, Zanzonico P, et al. Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort. Eur J Nucl Med Mol Imaging. 2008; 35: 39-46
|
|
|
|
|
|
25) Mahy P, Geets X, Lonneux M, et al. Determination of tumour hypoxia with [18F]EF3 in pat-ients with head and neck tumours: a phase I study to assess the tracer pharmacokinetics, biodistribution and metabolism. Eur J Nucl Med Mol Imaging. 2008; 35: 1282-9
|
|
|
|
|
|
26) Le QT, Moon J, Redman M, et al. Phase II study of tirapazamine, cisplatin, and etoposide and concurrent thoracic radiotherapy for limited-stage small-cell lung cancer: SWOG 0222. J Clin Oncol. 2009; 27: 3014-9
|
|
|
|
|
|
27) Rischin D, Hicks RJ, Fisher R, et al. Prognostic significance of [18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98. 02. J Clin Oncol. 2006; 24: 2098-104
|
|
|
|
|
|
28) Patterson AV, Ferry DM, Edmunds SJ, et al. Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. Clin Cancer Res. 2007; 13: 3922-32
|
|
|
|
|
|
29) Toma-Dasu I, Dasu A, Brahme A. Dose prescription and optimisation based on tumour hypoxia. Acta Oncol. 2009; 48: 1181-92
|
|
|
|
|
|
30) Lee NY, Mechalakos JG, Nehmeh S, et al. Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2008; 70: 2-13
|
|
|
|
|
|
31) Lin Z, Mechalakos J, Nehmeh S, et al. The influence of changes in tumor hypoxia on dose-painting treatment plans based on 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys. 2008; 70: 1219-28
|
|
|
|
|
|
32) Roels S, Slagmolen P, Nuyts J, et al. Biological image-guided radiotherapy in rectal cancer: is there a role for FMISO or FLT, next to FDG？ Acta Oncol. 2008; 47: 1237-48
|
|
|
|
|
|
33) Birner P, Gatterbauer B, Oberhuber G, et al. Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer. 2001; 92: 165-71
|
|
|
|
|